BR112017002926A2 - composições e método para aprimorar o perfil de liberação farmacocinético inicial in vivo - Google Patents
composições e método para aprimorar o perfil de liberação farmacocinético inicial in vivoInfo
- Publication number
- BR112017002926A2 BR112017002926A2 BR112017002926A BR112017002926A BR112017002926A2 BR 112017002926 A2 BR112017002926 A2 BR 112017002926A2 BR 112017002926 A BR112017002926 A BR 112017002926A BR 112017002926 A BR112017002926 A BR 112017002926A BR 112017002926 A2 BR112017002926 A2 BR 112017002926A2
- Authority
- BR
- Brazil
- Prior art keywords
- vivo
- enhancing
- compositions
- release profile
- pharmacokinetic release
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 230000002708 enhancing effect Effects 0.000 title 1
- 238000001727 in vivo Methods 0.000 title 1
- 229940002612 prodrug Drugs 0.000 abstract 4
- 239000000651 prodrug Substances 0.000 abstract 4
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 abstract 3
- 229960004372 aripiprazole Drugs 0.000 abstract 3
- 239000002245 particle Substances 0.000 abstract 3
- 239000003381 stabilizer Substances 0.000 abstract 3
- 230000007928 solubilization Effects 0.000 abstract 1
- 238000005063 solubilization Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462038665P | 2014-08-18 | 2014-08-18 | |
| EP14181328 | 2014-08-18 | ||
| PCT/EP2015/068872 WO2016026822A1 (en) | 2014-08-18 | 2015-08-17 | Aripiprazole prodrug compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017002926A2 true BR112017002926A2 (pt) | 2017-12-12 |
Family
ID=51352472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017002926A BR112017002926A2 (pt) | 2014-08-18 | 2015-08-17 | composições e método para aprimorar o perfil de liberação farmacocinético inicial in vivo |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20220079939A1 (enExample) |
| EP (2) | EP3508196B1 (enExample) |
| JP (1) | JP6571166B2 (enExample) |
| CN (3) | CN112494492B (enExample) |
| AU (1) | AU2015306198B2 (enExample) |
| BR (1) | BR112017002926A2 (enExample) |
| CY (1) | CY1124625T1 (enExample) |
| DK (1) | DK3508196T3 (enExample) |
| ES (1) | ES2884849T3 (enExample) |
| HR (1) | HRP20211271T1 (enExample) |
| HU (1) | HUE055711T2 (enExample) |
| IL (2) | IL292079B2 (enExample) |
| MX (1) | MX371417B (enExample) |
| PL (2) | PL3508196T3 (enExample) |
| PT (1) | PT3508196T (enExample) |
| RS (2) | RS62232B1 (enExample) |
| RU (1) | RU2705376C2 (enExample) |
| SI (2) | SI3508196T1 (enExample) |
| SM (2) | SMT202100481T1 (enExample) |
| WO (1) | WO2016026822A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201905694T4 (tr) * | 2014-08-18 | 2019-05-21 | Alkermes Pharma Ireland Ltd | Aripiprazol ön ilaç bileşimleri. |
| US10016415B2 (en) | 2014-08-18 | 2018-07-10 | Alkermes Pharma Ireland Limited | Aripiprazole prodrug compositions |
| ES2893973T3 (es) | 2016-02-17 | 2022-02-10 | Alkermes Pharma Ireland Ltd | Composiciones de múltiples profármacos de aripiprazol |
| CN110025572A (zh) * | 2018-01-11 | 2019-07-19 | 四川科伦药物研究院有限公司 | 月桂酰阿立哌唑混悬剂及其制备方法 |
| US11273158B2 (en) * | 2018-03-05 | 2022-03-15 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
| CN110327296B (zh) * | 2019-08-06 | 2021-10-22 | 深圳市泛谷药业股份有限公司 | 一种阿立哌唑长效注射制剂及其制备方法 |
| KR20240018523A (ko) | 2021-06-08 | 2024-02-13 | 추가이 세이야쿠 가부시키가이샤 | 다이하이드로피리다진-3,5-다이온 유도체를 함유하는 제제 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| NZ248813A (en) | 1992-11-25 | 1995-06-27 | Eastman Kodak Co | Polymeric grinding media used in grinding pharmaceutical substances |
| US5336507A (en) | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
| US5718388A (en) | 1994-05-25 | 1998-02-17 | Eastman Kodak | Continuous method of grinding pharmaceutical substances |
| TW384224B (en) | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
| US5662883A (en) | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
| US5560932A (en) | 1995-01-10 | 1996-10-01 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents |
| US5665331A (en) | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
| US5534270A (en) | 1995-02-09 | 1996-07-09 | Nanosystems Llc | Method of preparing stable drug nanoparticles |
| US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| US5543133A (en) | 1995-02-14 | 1996-08-06 | Nanosystems L.L.C. | Process of preparing x-ray contrast compositions containing nanoparticles |
| KR100508910B1 (ko) | 1995-10-17 | 2006-04-20 | 알티피 파마 코포레이션 | 불용성약물방출 |
| GB9622173D0 (en) | 1996-10-24 | 1996-12-18 | Glaxo Group Ltd | Particulate Products |
| AU2002334939A1 (en) * | 2001-10-12 | 2003-04-22 | Eugene R. Cooper | Compositions having a combination of particles for immediate release and for controlled release |
| US20050032811A1 (en) * | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
| PL1675573T4 (pl) | 2003-10-23 | 2016-04-29 | Otsuka Pharma Co Ltd | Sterylny preparat do wstrzykiwań arypiprazolu o kontrolowanym uwalnianiu i sposób |
| EP1933814A2 (en) * | 2005-09-15 | 2008-06-25 | Elan Pharma International Limited | Nanoparticulate aripiprazole formulations |
| SMT201700430T1 (it) | 2009-06-25 | 2018-01-11 | Alkermes Pharma Ireland Ltd | Composti eterociclici per il trattamento di disturbi neurologici e psicologici |
| HUE032109T2 (en) * | 2011-03-18 | 2017-08-28 | Alkermes Pharma Ireland Ltd | Injectable pharmaceutical compositions containing water insoluble antipsychotic, sorbitan laurate and polysorbate 20 |
| EP2827868B8 (en) * | 2012-03-19 | 2019-12-18 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty acid esters |
| WO2013142205A1 (en) * | 2012-03-19 | 2013-09-26 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising benzyl alcohol |
| ES2792149T3 (es) * | 2012-09-19 | 2020-11-10 | Alkermes Pharma Ireland Ltd | Composiciones farmacéuticas que tienen estabilidad de almacenamiento mejorada |
-
2015
- 2015-08-17 DK DK19154013.7T patent/DK3508196T3/da active
- 2015-08-17 PT PT191540137T patent/PT3508196T/pt unknown
- 2015-08-17 ES ES19154013T patent/ES2884849T3/es active Active
- 2015-08-17 IL IL292079A patent/IL292079B2/en unknown
- 2015-08-17 RU RU2017108204A patent/RU2705376C2/ru active
- 2015-08-17 CN CN202011416673.7A patent/CN112494492B/zh active Active
- 2015-08-17 EP EP19154013.7A patent/EP3508196B1/en active Active
- 2015-08-17 RS RS20210956A patent/RS62232B1/sr unknown
- 2015-08-17 CN CN202011448652.3A patent/CN112641785A/zh active Pending
- 2015-08-17 BR BR112017002926A patent/BR112017002926A2/pt not_active Application Discontinuation
- 2015-08-17 RS RS20190505A patent/RS58746B2/sr unknown
- 2015-08-17 PL PL19154013T patent/PL3508196T3/pl unknown
- 2015-08-17 SI SI201531670T patent/SI3508196T1/sl unknown
- 2015-08-17 EP EP15750750.0A patent/EP3182958B2/en active Active
- 2015-08-17 JP JP2017509024A patent/JP6571166B2/ja active Active
- 2015-08-17 SM SM20210481T patent/SMT202100481T1/it unknown
- 2015-08-17 HU HUE19154013A patent/HUE055711T2/hu unknown
- 2015-08-17 SI SI201530711T patent/SI3182958T2/sl unknown
- 2015-08-17 CN CN201580055491.2A patent/CN106794251B/zh active Active
- 2015-08-17 WO PCT/EP2015/068872 patent/WO2016026822A1/en not_active Ceased
- 2015-08-17 HR HRP20211271TT patent/HRP20211271T1/hr unknown
- 2015-08-17 AU AU2015306198A patent/AU2015306198B2/en active Active
- 2015-08-17 MX MX2017002029A patent/MX371417B/es active IP Right Grant
- 2015-08-17 SM SM20190236T patent/SMT201900236T1/it unknown
- 2015-08-17 PL PL15750750.0T patent/PL3182958T5/pl unknown
-
2017
- 2017-02-14 IL IL250607A patent/IL250607B/en unknown
-
2021
- 2021-08-23 CY CY20211100753T patent/CY1124625T1/el unknown
- 2021-10-12 US US17/450,683 patent/US20220079939A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017002926A2 (pt) | composições e método para aprimorar o perfil de liberação farmacocinético inicial in vivo | |
| PH12018501226A1 (en) | Methods for treating huntingtons disease | |
| MX2021006697A (es) | Composición y método para el crecimiento del cabello. | |
| BR112017009277A2 (pt) | compostos de silicone | |
| BR112016024357A2 (pt) | composições de insulina de ação rápida | |
| BR112017006061A2 (pt) | agente terapêutico indutor de citotoxicidade | |
| BR112016013684A2 (pt) | Solução aquosa ou hidrocoloide, método para aumentar a viscosidade de uma composição e método para o tratamento de um material | |
| EA201792501A1 (ru) | Вакцины для лечения и профилактики рака | |
| HK1255162A1 (zh) | 爱帕琳肽受体激动剂及使用方法 | |
| MX2021002455A (es) | Metodos para tratar tumores de celulas epitelioides. | |
| MX2020009223A (es) | Anticuerpos anti-fgfr2iiib afucosilados. | |
| BR112015016466A2 (pt) | método para o tratamento de câncer baseado no estado de mutação de k-ras | |
| IL247721B (en) | Compositions comprising solid dispersions of (s)-n-((s)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyanopyridin-2-yl)-n-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide for use in the treatment of advanced solid tumors | |
| BR112016012528A2 (pt) | composto imunogênico | |
| JP2014235432A5 (enExample) | ||
| BR112015031278A8 (pt) | compostos e nanopartículas de platina com base em lipídio | |
| EA201791058A1 (ru) | Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4) | |
| HK1220155A1 (zh) | 治疗癌症的方法 | |
| PH12018000197A1 (en) | Hand, foot, and mouth vaccines and methods of manufacture and use thereof | |
| CY1120759T1 (el) | Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης | |
| AU2016380190A8 (en) | Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof | |
| BR112017028224A2 (pt) | composição, e, método para proteger um leitão contra uma doença associada a pestivírus. | |
| BR112017000462A2 (pt) | detergente para lavar louça de pastilha e métodos para a fabricação e uso do mesmo | |
| PH12017501601A1 (en) | Use of isolated fractions of mastic gum for treating optic neuropathy | |
| ZA202002129B (en) | Oral bendamustine formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |